Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?

DISCUSSION: Pandemic-driven treatment protocols provide a unique opportunity to assess the utility of bridging endocrine therapy for resectable HR+/HER2- tumors. Differences in clinical and pathologic staging were similar across groups and did not appear to be affected by receipt of NAET. Our limited cohort demonstrates this strategic therapeutic avenue can optimize health care utilization and may be a reasonable approach when delaying surgery is preferred.PMID:34587799 | DOI:10.1177/00031348211047205

Source: The American Surgeon - September 30, 2021 Category: Surgery Authors: Kathleen A Iles Madeline Thornton Jihye Park Mya Roberson Philip M Spanheimer David W Ollila Kristalyn Gallagher Source Type: research